AstraZeneca's former antibiotics unit claims a PhIII win in drug-resistant bacteria affecting sickly patients

The management team at Entasis, AstraZeneca’s old antibiotics unit spun out six years ago, has a new dataset it’s simply delighted to share.

Entasis revealed Phase III data outlining how an antibiotic for infections caused by Acinetobacter baumannii reached its primary endpoint of non-inferiority. Researchers compared the program — known as sulbactam-durlobactam or SUL-DUR — to the antibiotic colistin, saying their drug saw lower levels of all-cause mortality after four weeks in treatment-resistant patients.